Global Study Shows Rising Acne Burden Through 2050
Research from Brigham and Women's Hospital indicates global acne cases and disability-adjusted life years rose over 60 percent since 1990.
By Giovanni Sapere
2 min readHuman-Edited, AI-Assisted
A cross-sectional study led by Brigham and Women's Hospital reveals that the global burden of acne vulgaris increased substantially between 1990 and 2023 and will continue expanding through 2050. Published in JAMA Dermatology, the findings underscore how skin conditions generate extensive morbidity, accelerating the demand for clinical innovation across global healthcare systems.
Quantifying the global surge in acne vulgaris
According to research published in JAMA Dermatology and reported by MedicalXpress, researchers examined records from the Global Burden of Disease (GBD) Study 2023 to evaluate trends in acne vulgaris, spotlighting an urgent demand for dermatological innovation. Lead author Pierina Parraga and her team at Brigham and Women's Hospital in Boston identified an estimated 54.4 million prevalent cases worldwide under the GBD 2023 definition, representing 674.1 per 100,000 persons.
The historical evaluation demonstrated steady upward shifts over three decades. From 1990 to 2023, global age-standardized incidence risks rose by 67.3%, prevalence risks grew by 63.6%, and disability-adjusted life year (DALY) rates increased by 63.5%, showing that the global impact of the condition has expanded significantly faster than baseline demographic growth alone as documented by MedicalXpress.
“Long-term forecasts remain uncertain, despite incorporating projected demographic changes; they do not propagate the uncertainty in GBD estimates or account for future changes in health care utilization or diagnoses”
— Pierina Parraga et al.
Comparative morbidity and demographic patterns
The investigation recorded 27.8 million incident cases in 2023, translating to 344.4 per 100,000 persons, with acne accounting for 1.17 million DALYs according to MedicalXpress. While acne presented no association with direct mortality, its cumulative non-fatal morbidity placed it among major contributors to global skin disease.
The DALY burden of acne surpassed that of basal cell carcinoma, which accounted for 2,612 DALYs globally, and matched the general magnitude of squamous cell carcinoma, melanoma, and psoriasis, which registered 1.33 million, 1.82 million, and 2.65 million DALYs respectively, as detailed by MedicalXpress. Furthermore, demographic findings highlighted that 56% of cases occurred among females and 44% among males.
Projections toward 2050 and clinical needs
Utilizing demography-plus-autoregressive integrated moving average modeling, the authors estimated that by 2050, annual incident cases will reach 37.5 million, prevalent cases will climb to 77 million, and total burden will reach 1.65 million DALYs globally, according to MedicalXpress. These persistent upward curves illustrate the growing necessity for sustained intellectual property development and translational research into therapeutic protocols.
Addressing this persistent skin condition also requires evaluating novel therapeutic interventions, including topical formulations and specialized medical device technologies intended to mitigate chronic symptoms, an area where each new biomedical patent plays an essential role. However, the study authors emphasized methodological boundaries regarding long-range forecasts, noting that future shifts in diagnostic patterns and healthcare utilization may alter real-world trajectory outcomes as reported by MedicalXpress.
Read also on The Patent: RolTine 2.0 Packs Dual Straight and Curved Measuring into a Titanium Chassis · Cal AI Founder Zach Yadegari Sells App and Launches Persona
